Jennifer Tremmel
Key Documents
Contact Information
-
Clinical Offices
Interventional Cardiology 300 Pasteur Dr MC 5218 H2103 Stanford, CA 94305 Tel Work (650) 723-0180 Fax (650) 725-6766
Professional Overview
Clinical Focus
- Cardiology (Heart)
- Women's Heart Health
- Women's Cardiovascular Disease
- Interventional Cardiology
Administrative Appointments
- Clinical Director, Women's Heart Health at Stanford (2007 - present)
- Director, Secondary Prevention Program (2006 - present)
Professional Education
| Board Certification: | Interventional Cardiology, American Board of Internal Medicine (2007) |
| Board Certification: | Cardiovascular Disease, American Board of Internal Medicine (2006) |
| Fellowship: | SUMC - Graduate Medical Education CA (2005) |
| Residency: | Dartmouth Hitchcock Medical Center NH (2001) |
| Internship: | Dartmouth Hitchcock Medical Center NH (1999) |
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Dr. Tremmel studies sex differences in cardiovascular disease. She is currently investigating sex differences in coronary endothelial function, plaque deposition, and the microcirculation of women and men who present with chest pain, but have normal appearing coronary arteries by angiography. She is also leading Stanfords participation in the multi-center VIRGO trial, which is evaluating sex differences in young patients who present with myocardial infarction. Other active research projects include sex differences in chronic total coronary occlusions, the impact of stress on anginal symptoms, and vascular access site complications. Dr. Tremmel keeps Stanfords Tako-tsubo Patient Registry and is conducting a multi-center study to investigate the relationship of stress and coping to genetic polymorphisms in patients with Tako-tsubo.
Clinical Trials
- Sex Differences in Coronary Pathophysiology Recruiting
- A Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety and Effectiveness of the Tryton Side Branch Stent used in Conjunction with a Drug-Eluting Stent Compared to Side Branch Balloon Angioplasty in Conjunction with a Drug-Eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within the Native Coronary Circulation Recruiting
- A Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety and Effectiveness of the Tryton Side Branch Stent used in Conjunction with a Drug-Eluting Stent Compared to Side Branch Balloon Angioplasty in Conjunction with a Drug-Eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within the Native Coronary Circulation Recruiting
- The use of the TAXUS Liberté stent in conjunction with a medication called prasugrel (Effient). Recruiting
- A Clinical Evaluation of the Medtronic Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Native Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm No longer recruiting
Publications
- Comparison of drug-eluting versus bare metal stents in cardiac allograft vasculopathy. Am J Cardiol. 2011; (5): 665-8
- Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease. Am J Cardiol. 2011; (11): 1552-5
- Do not be deceived by the cunning jailed side branch. Catheter Cardiovasc Interv. 2011; (5): 727-8
- Images in intervention. Intramural hematoma appearing as a new lesion after coronary stenting. JACC Cardiovasc Interv. 2011; (1): 129-30
- Sex differences in neointimal hyperplasia following endeavor zotarolimus-eluting stent implantation. Am J Cardiol. 2011; (7): 912-7
Help